Latest Production News

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Savannah Goldfields Limited has announced a $15 million equity raising through a placement and conditional placement, offering free attaching options subject to shareholder approval. The capital raise aims to strengthen the company’s financial position and support its operational restart plans.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Mayfield Group Holdings Ltd has reported a landmark financial year with revenues soaring nearly 38% and profits climbing over 32%, driven by strong demand in Data Centres and AI infrastructure sectors.

Zimplats Holdings Limited reported a strong financial rebound in FY2025, with revenue up 8% and net profit surging 393%, even as mined volumes dipped and no dividend was declared.

Global Health Limited reports solid progress towards profitability in FY2025, driven by a 6% increase in subscription revenue and strategic AI integration across its healthcare platforms.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

AXP Energy has updated its resource disclosures and is accelerating its gas-to-power strategy to fuel bitcoin mining operations in Oklahoma, leveraging proven oil fields and strong industry partnerships.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.